Prolactin is essential for normal mammary gland development and differentiation, and has been shown to promote tumor cell proliferation and chemotherapeutic resistance. Soluble isoforms of the prolactin receptor (PrlR) have been reported to regulate prolactin bioavailability by functioning as 'prolactin-binding proteins'. Included in this category is D7/11, a product of alternate splicing of the PrlR primary transcript. However, the direct interactions of prolactin with D7/11, and the resulting effect on cell behavior, have not been investigated. Herein, we demonstrate the ability of D7/11 to bind prolactin using a novel proximity ligation assay and traditional immunoprecipitation techniques. Biochemical analyses demonstrated that D7/11 was heavily glycosylated, similar to the extracellular domain of the primary PrlR, and that glycosylation regulated the cellular localization and secretion of D7/11. Low levels of D7/11 were detected in serum samples of healthy volunteers, but were undetectable in human milk samples. Expression of D7/11 was also detected in six of the 62 primary breast tumor biopsies analyzed; however, no correlation was found with D7/11 expression and tumor histotype or other patient demographics. Functional analysis demonstrated the ability of D7/11 to inhibit prolactin-induced cell proliferation as well as alter prolactin-induced rescue of cell cycle arrest/early senescence events in breast epithelial cells. Collectively, these data demonstrate that D7/11 is a novel regulatory mechanism of prolactin bioavailability and signaling. Key Words " prolactin " prolactin receptor " mammary " alternative splicing " prolactin-binding protein Journal of Molecular Endocrinology (2013) 50, 79-90 Journal of Molecular Endocrinology Research J M FLEMING and others D7/11, a prolactin-binding protein 50:1 79-90 Research J M FLEMING and others D7/11, a prolactin-binding protein 50:1 81 Research J M FLEMING and others D7/11, a prolactin-binding protein 50:1 82
Introduction
Prolactin is a ubiquitous and pleiotropic polypeptide hormone that plays a critical role in breast development, differentiation, and lactation (Das & Vonderhaar 1997 , Trott et al. 2008 . It is produced by lactotrophic cells within the anterior pituitary, as well as by many extrapituitary tissues including the mammary epithelium, skin, placenta, uterus, brain, and immune cells (Oakes et al. 2008) . Through the use of diverse animal models, over 300 functions have been identified for prolactin, including an influence on behavior, electrolyte balance, the regulation of metabolism, and immune response (Bole-Feysot et al. 1998 , Bernichtein et al. 2010 . The co-expression of the prolactin receptor (PrlR) in these tissues suggests that an autocrine-paracrine loop of action exists (Hovey et al. 2002 , Oakes et al. 2008 , Trott et al. 2008 . However, due to the inability to distinguish between pituitary and extrapituitary prolactin (Bernichtein et al. 2010) and the difficulty in detecting the protein in tissue culture models (Ginsburg & Vonderhaar 1995) , our comprehension of the physiological role of extrapituitary prolactin, as well as its regulation, remains poorly understood.
The PrlR is a member of the type-1 cytokine receptor superfamily, which includes the receptors for GH, colonystimulating factor, and interleukins (Bole-Feysot et al. 1998) . These receptors are single-chain transmembrane proteins that consist of an extracellular, a transmembrane, and an intracellular domain (Vonderhaar et al. 1985 , Trott et al. 2004 . Upon ligand binding, receptor homodimerization occurs and cell signaling is induced through the activation of receptor-associated kinases. The canonical prolactin signaling pathways include Jak2/ STAT5, c-Src/Fyn, PI3K/AKT, Nek3-Rac1, and Grb2-MAPK pathways (Hennighausen et al. 1997 , Harris et al. 2004 , Nguyen et al. 2008 . Adding to the complexity of this multifaceted role of prolactin, the primary transcript of the PrlR has alternative splice products that yield different lengths of the cytoplasmic tails, each of which are reported to have distinctive signaling properties (Clevenger et al. 2009 ).
Autocrine/paracrine regulation of bioavailable extrapituitary prolactin to its receptor has been proposed to be regulated by soluble forms of the PrlR (Dannies 2001 , Kline & Clevenger 2001 , Trott et al. 2003 . This mechanism of regulation has been demonstrated for many proteins including tumor necrosis factor-a, ciliary neutrophic factor, GH, leptin, interleukins 1, 2, and 6, transferrin, and nerve growth factor (Rose-John & Heinrich 1994 , Dannies 2001 ). These soluble receptor 'binding proteins' are generated either by alternate splicing of mRNA for the receptor or through post-translational proteolytic cleavage of the extracellular domain (ECD) of the receptor. To date, two prolactin-binding proteins (PrlBPs) have been described in human serum, milk, and cell lysates (Kline & Clevenger 2001 , Trott et al. 2003 . Kline & Clevenger (2001) first characterized a PrlBPs in human serum and milk by co-precipitating PrlBPs with antibodies generated against human prolactin and the ECD of the human PrlR, as well as by demonstrating the binding affinity of the PrlBPs for prolactin and GH. The structural properties of the PrlBPs were confirmed using limited proteolysis and mass spectrometry, and the ability of PrlBPs to antagonize the growth-promoting function of prolactin was demonstrated in a cell culture model (Kline & Clevenger 2001) .
A second soluble form of the PrlR was subsequently described (Trott et al. 2003) . This PrlR isoform results from alternative splicing of the mRNA from exon 7 to exon 11, thus giving its name D7/11. Expression of D7/11 has been reported in human colon and breast tumor samples, as well as in tumor-associated histologically normal breast tissue. Fluorescent immunohistochemistry illustrated a vesiculated intracellular distribution, consistent with its fate as a secreted protein. Similar to the previously identified human PrlBP, D7/11 was shown to bind to GH. However, its binding affinity for prolactin and the physiological function are yet to be described.
Herein, we demonstrate the ability of D7/11 to directly bind prolactin using novel proximity ligation assays and traditional immunoprecipitation techniques. The biochemical properties and relative binding affinities of D7/11 for prolactin were investigated. D7/11 was found to be glycosylated and was not detectable in human milk, two properties that distinguish it from PrlBP. Furthermore, we demonstrate the ability of D7/11 to alter the prolactin-induced cell proliferation and signaling of breast cancer cells.
Materials and methods
Cell culture T47D, MDA MB231, MCF7, Hs578t, and Chinese hamster ovary K1 (CHO) cell lines were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured as recommended. Cells were passaged using trypsinization (0.05% trypsin-EDTA; Invitrogen) and counted on a hemocytometer using trypan blue exclusion.
Production of recombinant D7/11
Recombinant protein was produced based on published data (Trott et al. 2003) , isolated, and purified by ProteinOne (Rockville, MD, USA) in their Escherichia coli expression system. Protein was validated via sequencing and western blot analysis.
Generation of human PrlR isoform overexpressing CHO cells and collection of conditioned media
Design of the flag-tagged human PrlR isoform constructs was described previously (Trott et al. 2003) . CHO cells were plated in normal growth medium. Twenty-four hour postplating, cells were transfected with either pEF6C (empty vector) or pEF6C-D7/11DNA using Fugene HD Transfection Reagent (Roche Applied Science). After 2 days of growth, stably transfected cells were selected in the presence of blasticidin (2 mg/ml; Invitrogen). The presence of the protein was confirmed via dot blot analysis using FLAG (Sigma) and PrlR isoform-specific antibodies (Antibody Production and Purification Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA). For collection of conditioned media, nearconfluent stably transfected CHO cells were washed and placed in serum-free media for 24 h. Media were collected, centrifuged to remove cells, and then directly used to treat the cells. When indicated, conditioned media were concentrated using an Amicon Ultra centrifugation filter (MWCO 10K; Millipore, Billerica, MA, USA).
Generation of human prolactin antibody
The prolactin antibody was produced by PRIMM (IMGEN Technologies, Cambridge, MA, USA) via immunization of rabbits with a recombinant His-tagged prolactin protein (residues 23-220, GI: 531103) and affinity column purified by the Antibody Production and Purification Unit (APPU; National Cancer Institute, Bethesda, MD, USA). Initial affinity column purification was followed by an additional purification using a GE Superdex 200 2.6/60 on an Akta Purifier (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) in PBS containing 0.1% sodium azide. The resulting antibody was validated by western blot analysis against the immunizing protein.
Solution-phase proximity ligation assay
All assay probes and reagents were purchased from Applied Biosystems and used as directed. Two sets of probes were used. The first set of probes was designed to detect D7/11 using the SF1a rabbit MAB and the commercially available mouse MAB that detect the ECD of the PrlR (Invitrogen Cat.# 35-9200). The second set of probes was designed to detect human prolactin and used the prolactin antibody (PRIMM) described above. Applied Biosystems linked the short DNA strands to the primary antibodies for detection. Each set of probes (primary antibodies linked to the DNA probe) was used for dual recognition of the target protein complex in situ, i.e. in their physiological context. If the DNA strands are in close proximity, they interact to form a unique DNA amplicon, which is subsequently amplified and detected by quantitative real-time PCR. The procedure is as follows. Briefly, diluted samples and the solutionphase proximity ligation assay (spPLA) probes (62.5 pM) were incubated overnight at 4 8C. The following day, ligation buffer mix was added to each well, incubated for 10 min at 37 8C, followed by the addition of protease to each well, incubation for 10 min at 37 8C, and then inactivated by a 5 min incubation at 95 8C. Samples were then mixed with TaqMan Fast PCR Master Mix (Life Technologies) and products measured using the StepOne-Plus Real Time PCR System (Life Technologies). Data were analyzed via the DCt method. Controls were reaction mixture alone and reaction mixture containing the probe pairs only (no protein added). For detection of D7/11 in human serum, a panel of normal and matched breast cancer serum samples was purchased from SeraCare Life Sciences, Inc. (Oceanside, CA, USA).
Proliferation assays
Breast cancer cells, proliferating in log phase, were placed in RPMI-1640 containing 0.01% charcoal-stripped serum (control media) for 24 h followed by 3 days of treatment. For treatment with conditioned media: cells were treated with fresh conditioned media from stably transfected CHO cells expressing either human D7/11 or the empty vector control in the presence or absence of 100 ng/ml of recombinant human prolactin. For treatment with recombinant protein, cells were treated with control media, control media with 100 ng/ml of prolactin, control media with 250 ng/ml of recombinant D7/11, or the combination. For all proliferation assays, cells were trypsinized and counted on a hemocytometer using trypan blue exclusion. Data represent three independent experiments GS.D.
Cell cycle analysis
For cell cycle analysis, 2!10 4 cells/cm 2 were plated in growth medium for 24 h and then washed and incubated in media containing 0.01% charcoal-stripped serum overnight. Cells were then treated with prolactin, D7/11, or the combination, as indicated, in media containing 0.01% charcoal-stripped serum for 3 days. Following the treatment, cells were washed in DPBS and fixed in 70% ethanol for 24 h to 3 days. On the day of analysis, cells were treated with RNase (100 U; Sigma) for 20 min at 37 8C, followed by incubation with propidium iodide (50 mg/ml in DPBS; Invitrogen) for 60 min at 4 8C. Prior to analysis on the FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA), cells were filtered through a 40 mm nylon mesh filter. Side and forward scatter were used to exclude cell debris/dead cells/clumps, and a second dot plot was employed to gate propidium iodide-positive cells. A minimum of 10 000 cells was acquired. The percentage of cells in the G 0 /G 1 , S, and G 2 /M phase, and CV were calculated using MODFIT-LT software (Verity Software House, Topsham, ME, USA).
Deglycosylation assays
Human milk (a kind gift from Dr Gilbert Smith; National Cancer Institute, Bethesda MD, USA), human serum, recombinant D7/11 protein, and conditioned media collected from CHO cells stably expressing D7/11 were subjected to deglycosylation using the PNGase kit from New England BioLabs (Ipswich, MA, USA) as directed. Briefly, samples were denatured for 10 min at 100 8C, followed by incubation with the PNGase enzyme cocktail for 1 h at 37 8C. Reducing sample buffer (Bio-Rad) was added, samples were incubated for 10 min at 90 8C, and then separated by SDS-PAGE. Proteins were transferred to PVDF membranes using the iBlot (Invitrogen) at P3, for 7 min. The membranes were blocked for 1 h in 5% milk in TBS buffer with 0.1% Tween (TBST) at room temperature, and then incubated with primary antibody (5 mg/ml of SF1a rabbit MAB) overnight at 4 8C, washed, incubated with the appropriate secondary antibody conjugated to Alexa680 (Invitrogen) in TBST with 5% milk for 1 h at room temperature, and then imaged using the Li-COR Odyssey (Lincoln, NE, USA). The membranes were then stripped with 1 M NaOH for 5 min, washed, probed with a PrlR antibody that recognized the ECD of all PrlR isoforms (5 mg/ml; Invitrogen), and imaged as described above.
For cell culture deglycosylation studies, T47D cells were transiently transfected with a FLAG-tagged human D7/11 construct (previously described in Trott et al. (2003) ). Three days post-transfection, cells were treated with 500 ng/ml of tunicamycin (Sigma) for 48 h. This concentration was previously determined to affect the glycosylation of proteins, and not protein synthesis (Banerjee et al. 1993) . Cells were treated for 2 days; conditioned media were collected and concentrated using the Amicon Ultra-10 filtration system (EMD Millipore). Cell lysates were collected and separated into membrane and cytosol fractions using the BioVision FractionPREP kit (Milpitas, CA, USA) as directed, and then analyzed via western blot as described below. For immunofluorescence detection of D7/11 localization, cells were briefly fixed in 100% methanol, washed, and then blocked in 1! PBS containing 5.0% goat serum and 1.0% BSA (blocking buffer) for 30 min at room temperature. Cells were then incubated with a 1:50 dilution of the primary antibody (anti-FLAG; Sigma) in 2% BSA and 2% goat serum overnight at 4 8C, washed with 1! PBS, and then incubated with the appropriate secondary antibody (anti-mouse Alexa Fluor 488; Invitrogen) at a 1:1000 dilution in blocking buffer for 30 min at room temperature. Coverslips were mounted using Prolong Gold antifade reagent with DAPI (Invitrogen). Imaging was performed using the Carl Zeiss LSM510 confocal imaging system (Carl Zeiss MicroImaging) at !20 magnification.
PCR analysis of breast tumor biopsies
Collection of patient samples was performed in accordance with the guidelines of the National Cancer Institute's Institutional Review Board, protocol OH99-C-NO57. Total RNA was isolated from tumor biopsies using the RNeasy kit (Qiagen) according to the manufacturer's instructions. RNA was reverse transcribed using MMLV reverse transcriptase (Invitrogen) and primed with oligo-dT and random hexamers (Invitrogen). cDNA was amplified using gene primers that recognize all three isoforms of the PrlR, as described in Trott et al. (2003) , and PCR Master Mix (Roche Applied Science). PCR data were analyzed via gel electrophoresis.
Western blotting
Equal concentrations of protein, as determined by the Bradford assay, were separated by SDS-PAGE under reducing conditions. Membranes were blocked in 5% non-fat milk in TBST for 1 h at room temperature, then incubated with primary antibody (P38, P-P38 (Tyr 182), and PERK, Santa Cruz; FLAG, Sigma; PSTAT5 and PAKT, Cell Signaling Technology) overnight at 4 8C in TBST C5% BSA, washed, and incubated with the appropriate secondary antibody conjugated to HRP (GE Healthcare) in TBST with 5% milk for 1 h at room temperature. Peroxidase activity was detected using the enhanced chemiluminescence detection system (ECL Plus, GE Healthcare) as directed. GAPDH was used as a control to show equal loading (Santa Cruz). Western blots were quantified using NIH ImageJ 64.
Immunoprecipitation
Recombinant human prolactin (500 ng) and recombinant human D7/11 (1 mg) were incubated alone or in combination with either the SF1a rabbit MAB (5 mg/ml) or a commercially available antibody directed against human prolactin (5 mg/ml, PRIMM) in PBS, overnight at 4 8C. The next day, protein A/G PLUS beads (Invitrogen) were added; samples were incubated for 1.5 h at 4 8C, and then washed in PBS. The immunobead complexes were pelleted, resuspended in reducing sample buffer (Bio-Rad), and the eluted proteins were subjected to SDS-PAGE and western blot analysis as described above. Primary antibodies were a PrlR ECD antibody (1:500; Invitrogen) or a polyclonal antibody directed against human prolactin (2 mg/ml). Secondary antibodies were goat anti-mouse FITC (1:3000; Invitrogen) or clean-blot secondary antirabbit (1:100; Pierce Biotechnology, Rockledge, IL, USA). Controls included beads incubated with the proteins but no antibody and beads incubated with normal rabbit serum. For conditioned media immunoprecipitation, the same procedure was performed with the following modifications: i) 800 ng of recombinant human prolactin, ii) 1.0 ml of concentrated conditioned media from D7/11-expressing CHO cells was the source of D7/11 and concentrated conditioned media from CHO cells expressing the empty vector were used as the control.
Statistical analysis
Data were evaluated for significance via t-tests or one-way ANOVA with the appropriate post hoc analysis (Tukey, Bonferroni) using GraphPad InStat Software version 3.0b (San Diego, CA, USA). Data were considered as significant at P!0.05.
Results
Evaluation of recombinant D7/11 and prolactin binding interactions D7/11 was identified as an alternative splice variant of the primary human PrlR transcript using RT-PCR of breast tumor tissue RNA (Trott et al. 2003) . Figure 1A illustrates the alternate splicing of the exons found within the discussed PrlR isoforms, and Fig. 1B shows the extracellular and intracellular domains present in the membrane bound and soluble PrlR variants (adapted from Trott et al. (2003) ). Bioinformatic analysis suggested that D7/11 was a secreted binding protein and the ability of D7/11 to bind the ligand was examined via immunoprecipitation of FLAG-tagged D7/11 with 125 I-labeled human GH (hGH). The results confirmed the ability of D7/11 to bind the ligand, and the ability of D7/11 to bind 125 I-hGH was competitively inhibited by the addition of ovine prolactin, suggesting that D7/11 was also binding prolactin (Trott et al. 2003) . However, the direct interaction of D7/11 with prolactin was not investigated. Therefore, to directly assess the ability of D7/11 to bind prolactin, a novel in-solution proximity ligation assay (spPLA) was used.
A MAB directed against the short form 1a isoform of the PrlR (SF1a) and a PrlR ECD antibody (ECD) were each linked to DNA strands to form the detection probes. Upon proximal binding of the probe pairs to their respective target proteins, the cDNA strands hybridize and are ligated to form a unique DNA amplicon, which is subsequently detected by quantitative real-time PCR. Based on the structure of the PrlR isoforms (Trott et al. 2004) , the SF1a and ECD set of probes will detect only the SF1a and D7/11 proteins. Initial optimization experiments demonstrated the detectable range of D7/11 protein, 2 pg-4 ng ( Fig. 2A) . Additional probes to detect human prolactin were developed using a human specific antibody (design/ production described in Materials and methods). The specificity of the prolactin probes to human prolactin compared with ovine prolactin was also evaluated, and the results show a preferential detection of human prolactin (Fig. 2B) . To further establish the selectivity of this assay, we next examined whether a similarly sized and relevant peptide hormone, hGH, could be detected in the assay. The results confirmed the specificity of the assay as the hGH was below detectable limits of the assay (Fig. 2C) .
Following optimization of the probes, we tested the ability of recombinant human D7/11 to directly interact with prolactin. As shown in Fig. 3A , in vitro incubation of D7/11 with prolactin resulted in a dose-dependent increase in the detection of protein interactions using the SF1a and prolactin probe pairs. The maximal detection of protein binding with 10 nM prolactin occurred at 500 nM D7/11. When using only prolactin-specific probes, a dose-dependent inhibition of prolactin detection was identified (Fig. 3B) . Collectively, these results demonstrate direct protein interactions of D7/11 and prolactin.
To confirm the results obtained from the spPLA assays, standard immunoprecipitation experiments were performed. Both recombinant D7/11 and D7/11-expressing CHO cell-conditioned media were tested for their ability to bind human prolactin. The two sources of D7/11 were incubated with prolactin and immunoprecipitated with either the prolactin antibody or the SF1a antibody, followed by western blot analysis using the PrlR ECD or human prolactin antibody. The results confirmed our observations from the spPLA assay, both sources of D7/11 bound to prolactin (Fig. 4) . Similar to the spPLA assays, we were unable to detect D7/11 when incubated with prolactin and immunoprecipitated with the prolactin antibody (Fig. 4, bottom panel) . The inability to detect D7/11 may be due to variations in the potency and form of D7/11 produced in mammals compared with the recombinant D7/11 produced by bacteria. The different sources of D7/11 may have altered the binding affinity or strength of the protein-protein interactions, which resulted in the loss of the protein complex during the co-immunoprecipitation procedure. Alternatively, additional posttranslational modifications of D7/11 by mammalian cells might have altered the binding affinity or physically blocked the binding site for the prolactin antibody to bind to its epitope on prolactin. For example, glycosylation (i.e. the addition of a carbohydrate to the D7/11 molecule) may cause a steric hindrance in the ability of the prolactin antibody to reach the epitope on prolactin when bound to glycosylated D7/11; therefore, only the free prolactin, not bound to D7/11, was able to be immunoprecipitated when the prolactin antibody was used to detect the prolactin and D7/11 interactions. 
Glycosylation of D7/11
Previous studies have described a PrlBP that is found in human serum and milk, and is not glycosylated despite the high level of glycosylation on the asparagine residues of the PrlR ECD (Buteau et al. 1998 , Kline & Clevenger 2001 . Therefore, the glycosylation status of D7/11 was investigated. D7/11-expressing CHO cell lysates and recombinant D7/11 were incubated in the presence or absence of peptide N-glycosidase F, and then evaluated for a shift in electrophoretic mobility by western blot analysis. D7/11 was detected using either the SF1a or PrlR ECD MAB, both of which recognize the lower molecular weight D7/11 in addition to other PrlR isoforms (SF1a, 57 kDa; D7/11, 39.1-40.6 kDa depending on glycosylation; Trott et al. (2004) ). As shown in Fig. 5 , CHO cell lysates repeatedly demonstrated a distinct shift in electrophoretic mobility when treated with the glycosidase, suggesting glycosylation of D7/11. The recombinant D7/11, produced in bacteria, lacked glycosylation. In addition to the cell lysates and recombinant D7/11, human serum and milk were treated with the glycosidase and tested for the presence of D7/11. D7/11 could not be detected in serum or milk via western blot analysis using either the SF1a or PrlR ECD MAB. However, consistent with previous reports (Kline & Clevenger 2001) , the PrlBP was detected in serum and milk and did not exhibit any shift in electrophoretic mobility (Fig. 5B) .
To analyze the functional significance of D7/11 glycosylation, enzymatic deglycosylation studies were performed in cultured cells. T47D cells were transiently transfected with FLAG-tagged D7/11 and grown in the presence or absence of 500 ng/ml of tunicamycin (Sigma) for 48 h. This concentration was previously determined to affect the glycosylation of proteins, and not protein synthesis (Banerjee et al. 1993) . Similar to previous studies showing that glycosylation is required for PrlR long-form membrane localization (Banerjee et al. 1993) , we show that the secretion and localization of D7/11 is regulated by glycosylation. Both western and immunofluorescence analyses show altered D7/11 localization upon treatment. Specifically, cells treated with tunicamycin had increased levels of D7/11 in the cytoplasm, and significantly 
Figure 4
Endogenous and recombinant D7/11 binds prolactin. Recombinant human prolactin (500 ng) and recombinant D7/11 (1 mg) alone or in combination were immunoprecipitated with either a prolactin antibody (hPrl; lanes 7-9) or a PrlR isoform antibody that recognizes D7/11 (SF1a; lanes 10-12). Immunobead complexes were dissociated, and the proteins detected via western blot analysis using an antibody directed against the ECD of the PrlR or a prolactin antibody. Top: representative western blots of recombinant proteins immunoprecipitated and analyzed with the indicated antibodies. Bottom: representative western blots of concentrated conditioned media (CM) from CHO-expressing cells as the source of D7/11. Controls: lanes 1-3, beads incubated with the proteins but no antibody; lanes 4-6, beads incubated with normal rabbit serum (NRS).
decreased levels of secreted D7/11 (P!0.05; Fig. 5C ). The shift in the molecular weight of D7/11 indicates deglycosylation. Immunocytofluorescence showed an increase in the punctate perinuclear localization of D7/11 compared with control cells, suggesting that non-glycosylated D7/11 accumulates in the Golgi area. Collectively, these data suggest that the functional mechanism of D7/11 glycosylation involves proper localization and secretion of the protein and has no effect on the ability of D7/11 to bind prolactin. We further examined human serum for the presence of D7/11 using the spPLA for enhanced detection. Ten serum samples from breast cancer patients and 13 healthy volunteer serum samples were analyzed. A control sample of serum supplemented with recombinant D7/11 was used as a positive control. Three of the healthy volunteer serum samples had low but detectable levels of D7/11 (Fig. 6 ), suggesting that in contrast to the PrlBP, D7/11 is not abundantly secreted into the circulation. D7/11 has also been identified in both breast tumors and the patientmatched, associated normal breast tissue (Trott et al. 2003) . To extend upon this initial observation and investigate D7/11 expression with clinical variables, we analyzed an additional 62 primary breast tumor biopsies for D7/11 expression. Consistent with previous results, w10% (6 of 62) of the tumors were positive for D7/11 expression ( Supplementary Figure 1 , see section on supplementary data given at the end of this article). No correlation was found with histotype (lobular vs ductal carcinomas), estrogen receptor positivity of the tumor cells, or with patient age.
D7/11 inhibits prolactin-stimulated proliferation
To begin to elucidate the functional role of D7/11, proliferation assays were performed. T47D breast cancer 
Figure 5
Endogenously produced D7/11 is glycosylated. (A) Samples were deglycosylated with PNGase F treatment and then subjected to western blot analysis using an antibody directed against the PrlR SF1a, which recognizes D7/11. (B) Membranes were stripped and reprobed using an antibody that recognizes the ECD common to the PrlR isoforms (anti-PrlR ECD). Serum, human serum; CM, concentrated conditioned media from CHO cells stably expressing D7/11; D7/11, recombinant D7/11 produced in E. coli. Approximate molecular weights: hPRLBP, 25 kDa; glycosylated D7/11, 39.1 kDa; glycosylated D7/11, 40.6 kDa. (C) T47D cells transiently transfected with FLAG-tagged D7/11 were treated with (C)/without (K) tunicamycin (500 ng/ml) for 48 h. Conditioned media were collected and concentrated, cell lysates were separated into membrane and cytosolic fractions. Representative western blots of cytosolic, membrane, and secreted proteins are shown. AKT, E-cadherin, and Ponceau S-stained membrane are shown as loading controls for cytosolic, membrane, and conditioned media respectively. Histogram shows the quantitation of the amount of D7/11 secreted from cells from three independent experiments (*P!0.05). (D) Representative images of T47D cells transiently transfected with FLAG-tagged D7/11, treated with (C)/without (K) tunicamycin for 48 h, and then analyzed via immunocytofluorescence. FLAG-tagged D7/11 stained with Alexa488 (green); DNA stained with DAPI (blue). cells were chosen, as they have been reported to readily respond to prolactin-stimulated proliferation (Das & Vonderhaar 1996 , Perks et al. 2004 . All cell lines used in the current study have been reported to express levels of prolactin mRNA or secrete low levels of autocrine prolactin (Clevenger et al. 1995 , Ginsburg & Vonderhaar 1995 , Shaw-Bruha et al. 1997 , Vonderhaar 1999 , Perks et al. 2004 . These studies have shown that in the short time, our cells were treated and the media collected (overnight under minimal media conditions), and that autocrine prolactin secretion is negligible at best. Thus, the finding that the negligible amounts of prolactin are secreted by the cells is not enough to demonstrate significant differences in cell proliferation between the control and D7/11-treated cells during the 3-day period observed. To observe maximal effects of the prolactin response, cells were incubated in 0.01% charcoal-stripped serum overnight prior to the treatment for 3 days. As shown in Fig. 7 , recombinant D7/11 had no effect on cell proliferation alone; however, D7/11 was able to completely inhibit prolactin-induced cell proliferation at all concentrations tested (25 and 250 ng/ml, P!0.05). As D7/11 was found to be glycosylated (Fig. 5) , we investigated whether the glycosylation would alter the observed inhibitory effect of D7/11 on prolactin-induced proliferation. D7/11expressing CHO cell-conditioned media were used as the source of D7/11, and both T47D and MDA MB231 breast cancer cells were treated with D7/11, prolactin, or the combination. Similar to the results obtained with the recombinant protein, D7/11 was found to significantly inhibit prolactin-induced cell proliferation in both cell lines (Fig. 7B) . The breast cancer cell response to prolactin was reduced overall, potentially due to other cytokines and growth factors secreted into the CHO cell-conditioned media. Lastly, to confirm our findings from the proliferation assays, cell cycle analysis was performed. T47D cells were treated similarly to the proliferation assays; however, the cells were fixed, stained with propidium iodide, and analyzed via flow cytometry 24 h post-treatment to observe initial cell cycle events. In agreement with the proliferation assays, prolactin stimulated an increase in the percentage of cells in the S phase, and D7/11 inhibited this response (Fig. 7C ).
D7/11 alters breast epithelial cell signaling
To investigate the mechanisms by which D7/11 influenced the prolactin-stimulated cell behavior, the pathways reported to be activated by prolactin were examined. T47D cells were incubated in media containing (A) T47D breast cancer cells were plated at 2!10 4 cells/cm 2 in growth media. Twenty-four hours post-plating, cells were washed, incubated overnight in media containing 0.01% charcoal-stripped serum, and then treated for 3 days as indicated. Cell number was determined via trypsinization and counting on a hemocytometer using trypan blue exclusion. Data represent meanGS.D. of three independent experiments. *Indicates significance between Prl and D7/11CPrl: P!0.05; **indicates significance between the control and Prl: P!0.05. (B) 24 h conditioned media were collected from CHO cells expressing either the empty vector (C, control) or the D7/11 expression vector (D7/11) and used to treat the cells. T47D and MDA MB231 breast cancer cells were plated at 2!10 4 cells/cm 2 in growth media for 24 h, washed, incubated in media containing 0.01% charcoal-stripped serum overnight, and then treated for 3 days as indicated. Cell number was determined as described in (A). Data represent meanGS.D. of three independent experiments. *Indicates significance between C and CCPrl: P!0.05; **indicates significance between CCPrl and D7/11 or D7/11CPrl: P!0.05. PrlZ100 ng/ml of prolactin. (C) The indicated breast cancer cell lines were cultured as described in (A) and treated as indicated for 24 h (C, serum-free media; Prl, 100 ng/ml of prolactin; D7/11, 250 ng/ml of recombinant D7/11). Following the treatment, cells were fixed, stained with propidium iodide, and analyzed via flow cytometry. Percentage of cells in the S phase was calculated using MODFIT-LT software. Data represent meanGS.D. of three independent experiments. *Indicates significance between Prl and all the other treatments: P!0.05. 0.01% charcoal-stripped serum for 24 h prior to the treatment for 5 and 60 min with prolactin, D7/11, or the combination. As shown in Fig. 8 , 24 h culture in low serum-containing media induced early-onset senescence events in the cells, as indicated by the phosphorylation of P38 in the control treatment groups. Treatment with prolactin was able to rescue a significant portion of the cells from P38-induced early senescence/cell cycle arrest as indicated by the significant reduction of P38 phosphorylation in the cell lysates. The addition of D7/11 had no significant effect on the cells compared with the controls. The combined treatment of D7/11 and prolactin resulted in levels of P38 phosphorylation similar to controls or cells treated with D7/11 alone, suggesting that the addition of D7/11 was able to inhibit the prolactin-induced rescue of early-onset senescence/cell cycle arrest events. This observation was the most prominent and consistent signaling mechanism observed across all cell lines tested. The basal activation/phosphorylation and prolactin-stimulated activation/phosphorylation of other common signaling pathways varied among the breast cell lines tested (AKT, STAT5, STAT3, and ERK1/2; Supplementary Figure 2 , see section on supplementary data given at the end of this article). This is potentially due to the autocrine secretion of prolactin as well as the expression levels of the various PrlR isoforms (Vonderhaar 1999 , Trott et al. 2004 ).
Discussion
The data presented in this study show direct interactions between prolactin and D7/11, a soluble isoform of the PrlR. We also demonstrate the glycosylation of D7/11 and its ability to inhibit prolactin-stimulated cell proliferation. Collectively, these data demonstrate a novel regulatory mechanism of prolactin bioavailability and signaling.
Similar to the PrlBP, the precise source of D7/11 generation in breast and colon tissues is unknown. In addition to the nine cell lines analyzed for D7/11 message in the initial report (Trott et al. 2003) , we screened an additional 12 breast cancer cell lines and two primary normal breast epithelial cell preparations from reduction mammoplasty tissue. Similar to the original report, we were unable to detect D7/11 via RT-PCR in these cells grown in vitro on tissue culture dishes (data not shown). This presents the possibility that the source of D7/11 in breast tissue originates from stromal or immune cells. Alternatively, as the polarity and 3D organization of epithelial cells is known to directly regulate gene expression (Rooney & Streuli 2011 , Schedin & Keely 2011 , the possibility remains that breast epithelial cells in a 3D organization or the appropriate extracellular matrix will produce D7/11. It is noteworthy that D7/11 has only been detected in organized tissues and not in monolayers of cells in culture. It is well recognized that prolactin signaling is altered when cells are cultured in 3D (Prince et al. 2002 , Katz & Streuli 2007 , Rooney & Streuli 2011 ; therefore, future studies exploring the role of D7/11 on prolactin regulation in polarized cells or on different extracellular matrices would be of interest to the field.
Multiple isoforms of prolactin have been identified in the circulation, with the 23 kDa isoform identified as the most prominent in humans (Fonseca et al. 1991) . Previous studies have shown that the 23 kDa protein is involved in classic prolactin functions, including exhibiting proliferative and pro-angiogenic properties. Conversely, the 16 kDa form of prolactin was demonstrated as a potent anti-proliferative and anti-angiogenic factor in various cell types both in vitro and in vivo (Bentzien et al. 2001 , Kim et al. 2003 , Clapp et al. 2006 , Nguyen et al. 2007 ). It would be of interest to investigate the binding affinity for D7/11 on these two functionally opposing prolactin isoforms. Our data suggest that D7/11 may have a higher affinity for the 23 kDa prolactin as we observed an inhibition of prolactin-stimulated proliferation in all cell types investigated. Furthermore, the 16 kDa prolactin is a cleavage product of the 23 kDa protein, proposed to be formed by the action of the protease cathepsin D (Piwnica et al. 2004) . Whether the binding of D7/11 to prolactin alters the enzymatic action of cathepsin D is yet to be investigated. These studies may help to elucidate the production and function of these two functionally opposing prolactins.
It is of note that D7/11 is glycosylated, though the function of this biochemical modification remains D7/11 inhibits prolactin-induced rescue of early senescence events in breast epithelial cells. Cells were plated at 2!10 4 cells/cm 2 in growth media. Twenty-four hour post-plating, cells were washed, incubated overnight in 0.01% charcoal-stripped serum, and then treated with serum-free media (C), serum-free media C100 ng/ml of prolactin (Prl), serum-free media unknown. The PrlBP is not glycosylated and has the ability to bind both prolactin and GH, as well as inhibit prolactinstimulated proliferation in a cell culture model (Kline et al. 2002) . In the present study, both the glycosylated and non-glycosylated forms of D7/11 were able to bind and inhibit prolactin. In an attempt to understand the functional role of D7/11 glycosylation, we observed the cellular localization of D7/11 in the presence of tunicamycin, an inhibitor of N-glycosylation. Previous studies showed that glycosylation of the asparagyl residues of the ECD of the PrlR is crucial for its cell surface localization, but has no effect on PrlR signaling (Cahoreau et al. 1994 , Buteau et al. 1998 . Similarly, we found that treatment of cells overexpressing D7/11 with tunicamycin resulted in the accumulation of protein in the Golgi area. This suggests that the levels of D7/11 secreted into the extracellular space can be controlled cell-autonomously by post-translational modifications. In addition to D7/11 glycosylation regulating cellular localization, one can hypothesize that the glycosylation may influence the binding affinities for the different forms of prolactin (16 or 23 kDa) or bind the ECDs of the different PrlR isoforms. Given the sequence similarity of D7/11 to the PrlR, and the ability of the various PrlR isoforms to homo-and hetero-dimerize, the direct interaction of D7/11 and the PrlR is yet another potential mechanism for enhancement or inhibition of prolactin signaling. Prolactin induces differentiation in mammary epithelial cells through the activation of the JAK/STAT5 signaling pathway (Vonderhaar & Ziska 1989) , and has been shown to activate other common proliferative signal transduction pathways in breast epithelial cells (AKT, ERK1/2) (Brisken & O'Malley 2010 , LaPensee & Ben-Jonathan 2010 . In our studies, we found that alterations in STAT signaling pathways varied across the cell lines (both basal activation and activation by prolactin). We hypothesize that that this is due to the varying amounts of endogenous prolactin secreted by each cell type, as well as the different levels of the PrlR isoforms produced in each cell (Vonderhaar 1999 , Trott et al. 2004 ). Nevertheless, one conclusive pattern was consistently observed in all cell lines tested: we found that the underlying mechanism of D7/11-induced inhibition of proliferation involved the regulation of P38 activation. Whether prolactin rescued the cells from cell cycle arrest or early senescence was not determined. However, our data suggest that prolactin was consistently able to rescue the cells from either cell cycle arrest/early senescence events while simultaneously inactivating P38 (i.e. dephosphorylation), thus leading to the observed increase in cell proliferation compared with control cells or cells treated with D7/11 alone. Conversely, D7/11 blocked the ability of prolactin to rescue the cells in all cell lines tested. The role of prolactin as an inducible survival factor in mammary cells is well known; however, our observation that prolactin may rescue cells from early senescent events via inactivation of P38 presents a unique and understudied mechanisms of prolactin signaling. More studies investigating this novel signaling mechanism are warranted.
In conclusion, we present data detailing the ability of D7/11, a soluble secreted form of the PrlR, to directly bind to prolactin and inhibit prolactin-induced cell proliferation. Unlike the previously reported PrlBP, D7/11 was found to be glycosylated. Lastly, the inability to detect D7/11 in human serum samples suggests that D7/11 is a tissue-specific factor responsible for the local regulation of prolactin function. These data highlight the role of D7/11 as a novel regulatory factor of prolactin bioavailability.
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